“We are delighted to welcome Marcy to the team, as she brings extensive experience in the leadership role of investor relations and corporate communications and a solid track record in building investor relations and other key external audiences,” said
“I am delighted to join Aadi at this pivotal stage in the company’s development, following the transition to public markets and then obtaining its first commercial product approval while advancing the pipeline of precision therapies in oncology,” said Graham. “I look forward to working with the team to deliver Aadi’s vision as we grow and take the next steps.”
About Aadi Bioscience
Aadi is a biopharmaceutical company specializing in precision therapies for genetically defined cancers. The primary goal of Aadi is to bring transformational therapies to cancer patients with alterations in the driver of the mTOR pathway where other mTOR inhibitors have not or cannot be effectively harnessed due to problems with pharmacology, effective drug delivery, safety or effective disease site targeting. In
Based on data from Aadi’s Phase 2 registration study, AMPECT, with FYARRO, and, following discussions with the FDA regarding other emerging data with FYARRO, Aadi launched PRECISION 1, a registration-agnostic, phase 2-directed trial against tumors in mTOR inhibitor naïve patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. More information about Aadi’s development pipeline can be found on Aadi’s website at www.aadibio.com and join us on Twitter and LinkedIn.
Aadi cautions you that certain statements included in this press release that are not a description of historical facts are forward-looking statements. These statements are based on Aadi’s current beliefs and expectations. Forward-looking statements include statements regarding: our plans and potential for success in commercializing FYARRO; expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO; our plans for the continued development and manufacturing of FYARRO; early reception of FYARRO in the physician community; results and timing of additional clinical trials, including the registration-led trial in patients harboring TSC1 Where TSC2 inactivate changes, timing and likelihood of regulatory filings and FYARRO approvals, including in potential additional guidance and potential filings in additional jurisdictions; and the sufficiency of our existing capital resources and expected timing to fund our future operating and capital expenditures. Actual results could differ materially from those anticipated in these forward-looking statements due to such risks and uncertainties, which include, but are not limited to: risks related to uncertainties associated with the clinical development and regulatory approval of FYARRO in indications additional indications, including potential delays in the initiation, enrollment and completion of clinical trials for additional indications; the risk that adverse reactions or unexpected side effects may occur during the marketing, development and testing of FYARRO; Aadi’s continued reliance on third parties to conduct additional clinical trials of FYARRO; risks associated with the inability to realize any value from FYARRO in light of the inherent risks and difficulties of successfully bringing product candidates to market; and risks related to the impact of the COVID-19 pandemic on Aadi’s operations, the biotechnology industry and the economy generally.
Additional risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements are included under “Risk Factors” in Aadi’s Form 10-Q filed on
All forward-looking statements contained in this press release speak only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This warning is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
FYARRO™ is a trademark of
2022 GlobeNewswire, Inc., source